{"analyses":[{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95.0","ciUpperLimit":"0.69","groupDescription":"Comparison of RFS time-to-event distribution between the 2 treatment arms (PD-L1-positive participants) was based on Cox regression model with treatment as a covariate stratified by stage (IIIA \\[\\>1 mm metastasis\\] vs. IIIB vs. IIIC 1-3 nodes vs. IIIC ≥4 nodes) as indicated at randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"One-sided p-value based on log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.54","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.0","upperLimit":"87.0","value":"83.8"},{"groupId":"OG001","lowerLimit":"71.0","upperLimit":"79.2","value":"75.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"428"},{"groupId":"OG001","value":"425"}],"units":"Participants"}],"description":"RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants with PD-L1-positive tumors in both treatment arms of Part 1.","dispersionType":"95% Confidence Interval","groups":[{"description":"In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.","id":"OG000","title":"Pembrolizumab"},{"description":"In Part 1, participants received placebo IV as post-surgery therapy Q3W.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants in Part 1 with PD-L1-positive tumors.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}